3B Blackbio DX Ltd
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
- Market Cap ₹ 1,192 Cr.
- Current Price ₹ 1,389
- High / Low ₹ 2,350 / 1,292
- Stock P/E 24.3
- Book Value ₹ 313
- Dividend Yield 0.29 %
- ROCE 25.8 %
- ROE 19.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 16.8%
Cons
- Dividend payout has been low at 7.82% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 | 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | 99 | |
| 21 | 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 46 | 48 | |
| Operating Profit | 1 | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 | 51 |
| OPM % | 6% | 7% | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 52% | 51% |
| 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 15 | 16 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 64 | 66 |
| Tax % | 14% | 23% | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | 28% | 25% | |
| 0 | 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | 49 | |
| EPS in Rs | 0.59 | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 55.57 | 57.14 |
| Dividend Payout % | 0% | 0% | 0% | 17% | 9% | 6% | 7% | 6% | 24% | 8% | 8% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 27% |
| 3 Years: | 6% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 70% |
| 5 Years: | 44% |
| 3 Years: | 14% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 64% |
| 5 Years: | 26% |
| 3 Years: | 60% |
| 1 Year: | 4% |
| Return on Equity | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 30% |
| 3 Years: | 17% |
| Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 260 |
| 7 | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | |
| 7 | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 27 | |
| Total Liabilities | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 |
| 4 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 156 |
| 20 | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 132 | |
| Total Assets | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | 43 | |
| -0 | -0 | -0 | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | -33 | |
| 0 | -0 | -1 | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | -3 | |
| Net Cash Flow | 0 | -0 | 0 | 0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 | 7 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 213 | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 | 138 |
| Inventory Days | 120 | 145 | 143 | 175 | 164 | 141 | 124 | |||||
| Days Payable | 189 | 218 | 203 | 186 | 69 | 66 | 28 | |||||
| Cash Conversion Cycle | 144 | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 | 235 |
| Working Capital Days | 144 | 175 | 205 | 247 | 253 | 287 | 275 | 65 | 162 | 241 | 215 | 169 |
| ROCE % | 7% | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11h - Window for Re-lodgement of Transfer Requests of Physical shares
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Oct - 3B BlackBio Dx Limited submitted RTA confirmation certificate under Reg 74(5) for quarter ended Sept 30, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Sep - Window for Re-lodgement of Transfer Requests of Physical Shares
-
Appointment Of Secretarial Auditor.
27 Sep - CMD Dhirendra Dubey re-appointed Nov 30, 2025–Nov 29, 2030; independent director and secretarial auditor appointed for 2025–30.
-
Announcement under Regulation 30 (LODR)-Change in Management
27 Sep - AGM approved reappointment of CMD Dhirendra Dubey (30 Nov 2025–29 Nov 2030); Mithla reappointed; Vivek Saihgal appointed independent director.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2025Transcript PPT REC
-
May 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Nov 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jul 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit